The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To evaluate whether smoked marijuana reduces pain in people with HIV-related peripheral neuropathy.
Condition or disease
Peripheral Nervous System DiseasesHIV Infections
Drug: Smoked Marijuana
Phase 1Phase 2
The study will include subjects with peripheral neuropathy caused either by HIV-disease or antiretroviral medication for the treatment of HIV. A neurologist will conduct a neurological and pain evaluation to determine eligibility for the study. Subjects who meet all eligibility criteria will be admitted to the General Clinical Research Center at San Francisco General Hospital for seven days. Subjects will be randomized (like a toss of a coin) to smoke marijuana or a placebo (cigarettes with no THC).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Be 18 years or older.
Diagnosis of HIV-related painful neuropathy.
Stable antiretroviral therapy or no antiretroviral therapy for at least 8 weeks.
Prior use of marijuana, at least 6 occasions in their lifetime prior to enrollment.
EXCLUSION CRITERIA: (Not allowed)
Current use of smoked tobacco products.
Current methadone treatment.
Use of smoked marijuana within 30 days of enrollment.
Diagnosis of diabetes mellitus.
Currently receiving treatment with corticosteroids.
Use of INH, dapsone or metronidazole within 8 weeks prior to enrollment.
Severe heart disease, uncontrolled high blood pressure or lung disease.